Abstract
FBM is a new antiepileptic drug that has been administered as add-on therapy in 14 pediatric patients affected by drug-resistant partial or generalized epilepsies. FBM reduced significantly the total seizure frequency in 40% of subjects and it appear to be well tolerated. The improvement has persisted for up to 12 months.
| Translated title of the contribution | Felbamate as add-on in drug-resistant epilepsies of childhood |
|---|---|
| Original language | Italian |
| Pages (from-to) | 197-199 |
| Number of pages | 3 |
| Journal | Bollettino - Lega Italiana contro l'Epilessia |
| Issue number | 95-96 |
| Publication status | Published - 1996 |
ASJC Scopus subject areas
- Clinical Neurology
Fingerprint Dive into the research topics of 'Felbamate as add-on in drug-resistant epilepsies of childhood'. Together they form a unique fingerprint.
Cite this
Cilio, M. R., Bonardi, R., & Vigevano, F. (1996). Il Felbamato nel trattamento delle epilessie resistenti in eta pediatrica. Bollettino - Lega Italiana contro l'Epilessia, (95-96), 197-199.